Wen Shen, MD, PhD, is a nephrologist at MedStar Georgetown University Hospital. In addition to her clinical responsibilities, she is an assistant professor of Nephrology at Georgetown University Medical Center.
Dr. Shen is actively involved in patient care and clinical research. Her clinical work focuses on patients with hypertension, chronic kidney disease (CKD), diabetic nephropathy, HIV-associated nephropathy, glomerulonephritis, and bone metabolism disorder in CKD.
Her interest in developing new drugs and therapies for patients with CKD has led to her involvement in several clinical and translational research projects. Currently, she is investigating a new approach to treat proteinuric kidney disease by inhibiting the urokinase-type plasminogen activator receptor. She is also conducting a phase II clinical trial on a drug to manage diuretic resistant-edema in patients who have congestive heart failure with or without CKD.
Dr. Shen has been honored with a Young Investigator Award from the Society for Experimental Biology and Medicine. Her research has been published in peer-reviewed journals, including the Journal of the American Society of Nephrology, and she has presented her work at multiple national conferences. Dr. Shen is a member of the American Society of Nephrology and the American Medical Association, and she is certified in Internal Medicine and Nephrology by the American Board of Internal Medicine. In addition to English, she is fluent in Chinese (Mandarin).
She received her MD and PhD from Fudan University School of Medicine in China. She completed her residency in Internal Medicine at Yale University/Bridgeport Hospital and a fellowship in Nephrology at Harvard Medical School/Beth Israel Deaconess Medical Center.
Dr. Shen’s research interests include
- Proteinuric kidney disease
- Chronic kidney disease and cancer
- Drug development
Effect of amiloride vs. triamterene on proteinuria in patients with proteinuric kidney disease
Dr. Shen is the principal investigator (PI) on this cross-over pilot study designed to investigate the effect of amiloride in reducing urinary protein excretion and preventing rapid progression of proteinuric kidney disease.
Treatment of patients with furosemide-resistant edema and congestive heart failure with or without chronic kidney disease
Dr. Shen is a co-PI on this clinical trial sponsored by the National Institutes of Health. This study will investigate the efficacy of extended-release torsemide in the treatment of patients with furosemide-resistant edema and congestive heart failure with or without chronic kidney disease.
Proteinuria: a risk factor for cancer incidence?
Dr. Shen is a PI on this cohort study designed to examine whether proteinuria and impaired kidney function are associated with increased cancer risk.
Lu F, Shen W, Lin S. Dysregulation of apoptosis: a possible mechanism leading to chronic progressive renal histological changes in lupus nephritis. Chinese Medical Journal, 2000,113: 1082. PMID: 11776141
Shen W, Brown N, Finn PA, Dice JF, Franch HA. Akt and mammalian target of rapamycin regulate separate systems of proteolysis in renal tubular cells. Journal of the American Society of Nephrology, 2006, 17:2414. PMID: 16885413
- Research Areas
- Other Medical